Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients

Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10–35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Lijun, Lei, Dan, Zhang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610029/
https://www.ncbi.nlm.nih.gov/pubmed/28969097
http://dx.doi.org/10.18632/oncotarget.19925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610029/
https://www.ncbi.nlm.nih.gov/pubmed/28969097
http://dx.doi.org/10.18632/oncotarget.19925

Ejemplares similares